Onconova's Rigosertib Misses Primary Endpoint - Analyst Blog

By
A A A
Share |

Onconova Therapeutics, Inc. ( ONTX ) recently provided results on its most advanced candidate, rigosertib, from the phase III study, ONTIME.

Rigosertib failed to meet its primary endpoint of significant improvement in median overall survival compared to best supportive care (BSC) in the ONTIME study. The multi-center, randomized, controlled ONTIME study evaluated patients with higher risk myelodysplastic syndromes (MDS) who had progressed on, failed or relapsed after prior therapy with hypomethylating agents (HMAs).

The median overall survival of 8.2 months for IV rigosertib plus BSC arm was not statistically significant when compared to 5.8 months for placebo.

However, the effects of the treatment were seen in certain subgroups. In a subgroup of patients who had progressed on or failed previous treatment with HMAs, the median overall survival was 8.5 months for IV rigosertib plus BSC arm compared with 4.7 months for placebo.

Further analysis is underway to identify potential survival benefit in other subsets of patients.

Additional details from the ONTIME study will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Onconova is developing rigosertib in partnership with Baxter International Inc. ( BAX ) (commercialization rights in Europe) and SymBio Pharmaceuticals (Japan and Korea). Onconova will commercialize in all other territories.

Rigosertib is also being evaluated in a phase III study for metastatic pancreatic cancer, phase II study for transfusion-dependent lower risk MDS, and a phase II study for head and neck cancers.

Onconova carries a Zacks Rank #3 (Hold). We expect investors to react negatively to this news. The stock is down in pre-market trading.

Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc. ( ECYT ) and Biogen Idec Inc. ( BIIB ). Both stocks carry a Zacks Rank #1 (Strong Buy).



BAXTER INTL (BAX): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

ONCONOVA THERAP (ONTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ASCO , BAX , BIIB , ECYT , ONTX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM